Eli Lilly and Company $LLY Shares Sold by First Hawaiian Bank

First Hawaiian Bank trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 93.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 494 shares of the company's stock after selling 7,564 shares during the period. First Hawaiian Bank's holdings in Eli Lilly and Company were worth $408,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. PNC Financial Services Group Inc. lifted its stake in Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares during the period. Vanguard Group Inc. lifted its stake in Eli Lilly and Company by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock valued at $65,432,218,000 after acquiring an additional 4,975,395 shares during the period. GAMMA Investing LLC increased its holdings in shares of Eli Lilly and Company by 103,831.6% during the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after purchasing an additional 14,852,076 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Eli Lilly and Company by 0.6% during the 1st quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company's stock valued at $10,495,261,000 after purchasing an additional 81,587 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Eli Lilly and Company by 15.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,084,880 shares of the company's stock valued at $5,469,527,000 after purchasing an additional 969,376 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $748.26 on Tuesday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $939.86. The firm has a market capitalization of $708.20 billion, a price-to-earnings ratio of 48.91, a PEG ratio of 1.05 and a beta of 0.47. The company has a fifty day simple moving average of $740.54 and a 200-day simple moving average of $774.30. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the firm earned $3.92 earnings per share. The company's revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were issued a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. Eli Lilly and Company's dividend payout ratio is presently 39.22%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks bought 1,632 shares of the company's stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the acquisition, the chief executive officer directly owned 546,601 shares of the company's stock, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director J Erik Fyrwald bought 1,565 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares of the company's stock, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 4,514 shares of company stock valued at $2,894,841. 0.14% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on LLY. Leerink Partnrs lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. Morgan Stanley reaffirmed an "overweight" rating and set a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price for the company. in a report on Sunday, August 17th. DZ Bank raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. Finally, Deutsche Bank Aktiengesellschaft cut their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $941.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.